Aap Implantate Ag · XETR:AAQ1

Aap Implantate — Q2 2017 Earnings Presentation

16 slides from Aap Implantate's earnings presentation, Aug 15, 2017

  1. Slide 1: aap Implantate AG Q2/H1 2017 Report Conference Call

    aap Implantate AG Q2/H1 2017 Report Conference Call Bruke Seyoum Alemu, CEO Marek Hahn, CFO Berlin, August 15, 2017

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual

  3. Slide 3: Implementation of Strategic Imperatives: Progress in Q2/H1 2017

    Implementation of Strategic Imperatives Progress in Q2/H1 2017 Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access  LOQTEQ®: Completion of portfolio with a focus on   Established Established countries: countries: Focus on DACH, traumaWestern Euro

  4. Slide 4: Financial Figures Q2/2017 (1/3)

    Financial Figures Q2/2017 (1/3) (in KEUR) Sales Q2/2017 Q2/2016 Change Sales (reported) 2,344 3,427 -32% less Q2/2016 initial sales revoked in Q4/2016 0 756 - Sales (like-for-like) 2,344 2,670 -12% Trauma 2,288 2,309 -1% North America and Europe 1,608 1,799 -11% Other 680 510 +33% Other (mainly disc

  5. Slide 5: Financial Figures Q2/2017 (2/3)

    Financial Figures Q2/2017 (2/3) (in KEUR and EUR million) EBITDA Q2/2017 Q2/2016 Change EBITDA -1,642 -1,390 -18% One-time effects 553* -95** >+100% Recurring EBITDA -1,089 -1,485 +27% *Includes risk provision for voluntary product recalls and costs for personnel measures **Includes Q2/2016 initial

  6. Slide 6: Financial Figures Q2/2017 (3/3)

    Financial Figures Q2/2017 (3/3) (EBITDA bridge Q2/2016 to Q2/2017 in KEUR) 6

  7. Slide 7: Financial Figures H1/2017 (1/3)

    Financial Figures H1/2017 (1/3) (in KEUR) Sales H1/2017 H1/2016 Change Sales (reported) 5,439 5,945 -9% less Q2/2016 initial sales revoked in Q4/2016 0 756 - Sales (like-for-like) 5,439 5,188 +5% Trauma 5,189 4,535 +14% North America and Europe 3,653 3,568 +2% Other 1,536 967 +59% Other (mainly disc

  8. Slide 8: Financial Figures H1/2017 (2/3)

    Financial Figures H1/2017 (2/3) (in KEUR and EUR million) EBITDA H1/2017 H1/2016 Change EBITDA -3,307 -3,561 +7% One-time effects 905* -18** >+100% Recurring EBITDA -2,402 -3,579 +33% *Includes risk provision for voluntary product recalls and costs for personnel measures **Includes Q2/2016 initial s

  9. Slide 9: Financial Figures H1/2017 (3/3)

    Financial Figures H1/2017 (3/3) (EBITDA bridge H1/2016 to H1/2017 in KEUR) 9

  10. Slide 10: Highlights H1/2017 (Balance Sheet)

    Highlights H1/2017 (Balance Sheet) • Total assets 06/30/2017: EUR 58.4 million (12/31/2016: EUR 63.9 million)  -9%  Non-current assets: Change EUR -0.5 million  Share of intangible assets in total assets: 19%  Healthy ratio  Tangible assets: EUR -0.2 million  lower investment against usual dep

  11. Slide 11: Highlights H1/2017 (Cash Flow)

    Highlights H1/2017 (Cash Flow) • Operating Cash Flow H1/2017: EUR -2.9 million (H1/2016: EUR -4.1 million)  Positive contribution from working capital reduction of EUR 0.6 million  main impact reduction of inventory of EUR +0.3 million, receivables EUR +0.8 million and payables EUR -0.5 million 

  12. Slide 12: Voluntary Public Share Buyback Offer

    Voluntary Public Share Buyback Offer And Subsequent Capital Reduction • Voluntary public share buyback offer: purchase of up to 2.25 million aap shares for EUR 1.52 per share • Transaction was oversubscribed with 3.9 million shares offered for buyback • aap’s shareholders participated in part of the

  13. Slide 13: Exploration of Strategic Alternatives

    Exploration of Strategic Alternatives • aap’s Management Board is currently exploring strategic alternatives for more value creation • Alternatives range from, among other things, co-development-/license agreements, joint venture agreements to corporate transactions (e.g. merger, share or asset deal

  14. Slide 14: Outlook FY/2017

    Outlook FY/2017 Q3/2017 – Sales: EUR 1.8 million – EUR 3.0 million (Q3/2016: EUR 2.9 million) – EBITDA: EUR -1.8 million – EUR -1.2 million (Q3/2016: EUR -1.8 million) FY/2017 – Sales: EUR 10.0 million – EUR 13.0 million (FY/2016: EUR 10.5 million) – EBITDA: EUR -6.5 million – EUR -4.5 million (FY/2

  15. Slide 15: Management Agenda 2017 and beyond

    Management Agenda 2017 and beyond Implementation of strategic imperatives Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access  LOQTEQ®: Completion of LOQTEQ® portfolio with a focus   Established Established countries: countries: Focus Focus on on

  16. Slide 16: Many thanks for your attention!

    Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 16

aap Implantate — Q2 2017 Earnings Presentation on 6ix